Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced Bladder Cancer Recurrence Following Radical Cystectomy
Lymph node resection was not associated with prognosis and efficacy of pembrolizumab in patients with bladder cancer. However, as the resection of more than 14 lymph nodes was associated with a poorer prognosis and reduced efficacy of pembrolizumab, treatment strategies should be carefully tailored based on the extent of lymph node dissection and the administration of neoadjuvant therapy.
Authors
- Taku Naiki
- Takashi Nagai (ORCID: https://orcid.org/0000-0001-8116-1751)
- Masaru Tomita (ORCID: https://orcid.org/0000-0003-3423-377X)
- Kazuki Odagiri (ORCID: https://orcid.org/0000-0001-9088-7570)
- Naoki Ito (ORCID: https://orcid.org/0000-0002-1884-8494)
- Yuji Hotta
- Takahiro Yasui
- Rena Okawa (ORCID: https://orcid.org/0000-0002-8634-209X)
- Yusuke Noda (ORCID: https://orcid.org/0000-0003-0401-6731)
- Nobuhiko Shimizu (ORCID: https://orcid.org/0000-0001-7280-2481)
- Yoko Furukawa‐Hibi (ORCID: https://orcid.org/0000-0002-2126-5652)
- Toshiki Etani (ORCID: https://orcid.org/0000-0002-2841-7006)
- Yoshihiko Tasaki (ORCID: https://orcid.org/0000-0002-1830-7452)
- Yosuke Sugiyama (ORCID: https://orcid.org/0000-0001-8436-5872)
- Yoshihisa Mimura
- Atsushi Okada
- Shuzo Hamamoto (ORCID: https://orcid.org/0000-0002-9968-7468)
Institutions
- Nagoya City University (JP)
- Anjo Kosei Hospital (JP)
- Nagoya Medical Center (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/invivo.14015
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00